AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AstraZeneca PLC

Drugs giant AstraZeneca ($AZN) is set to report its Q2 earnings next week – July 27. Let’s look at what investors should expect. The company’s shar...

AstraZeneca Reports Q2 Earnings Next Week. What Investors Should Expect.

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. AstraZeneca’s new DEBATE study tracks Greek patients with chronic si...

AstraZeneca’s DEBATE Study Signals Long‑Term Bet on Precision Sinus Care

In a report released today, Michael Leuchten from Jefferies maintained a Buy rating on AstraZeneca, with a price target of £175.00. According to Ti...

Jefferies Sticks to Its Buy Rating for AstraZeneca (AZN)

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. The study titled “A Multicenter Non-interventional Single-arm Retrospectiv...

AstraZeneca Halts Russian NMOSD Study: What It Means for AZN Investors

J.P. Morgan analyst Richard Vosser maintained a Buy rating on AstraZeneca today and set a price target of £123.80. According to TipRanks, Vosser is...

J.P. Morgan Sticks to Their Buy Rating for AstraZeneca (AZN)

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. AstraZeneca has completed a mid-stage study testing AZD6234 for people liv...

AstraZeneca’s AZD6234 Obesity Trial Reaches Key Milestone, Raising New Market Hopes

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. AstraZeneca (AZN) has launched EvoPAR-Prostate05, a Phase III study ...

AstraZeneca’s New Saruparib Trial Targets Next Wave of Prostate Cancer Growth

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. This phase 2 study, officially titled “A Phase 2, Open-Label Study t...

AstraZeneca Backs New EGFR Lung Cancer Combo In Fresh Phase 2 Trial

In a report released today, Sarita Kapila from Morgan Stanley maintained a Buy rating on AstraZeneca, with a price target of p15,300.00. According ...

Morgan Stanley Remains a Buy on AstraZeneca (AZN)

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. AstraZeneca is advancing a new Phase III study called Eluminate-4 to...

AstraZeneca’s Eluminate-4 Trial Targets High-Risk Diabetes Patients, Raising Long-Term Upside for AZN

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. AstraZeneca plc (AZN) has launched Eluminate-5, a Phase III trial te...

AstraZeneca’s Eluminate-5 Trial: A New Combo Bid in Type 2 Diabetes

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. AstraZeneca is running a Phase III trial called “Eluminate-1” to tes...

AstraZeneca Advances Eluminate-1 Phase III Trial in Type 2 Diabetes

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. AstraZeneca updates its clinical work on asthma care for children. T...

AstraZeneca Completes Key Pediatric Asthma Inhaler Study, Setting Up Next Moves for Symbicort

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Sell rating on AstraZeneca, with a price target of £115.00. Papadaki...

AstraZeneca (AZN) Gets a Sell from Deutsche Bank

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. The Phase III Eluminate-2 study, officially titled “A Randomized, Op...

AstraZeneca’s Elecoglipron Takes On Semaglutide in Key Phase III Diabetes Trial

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. AstraZeneca plc (AZN) is running a new early-stage trial in Japan ca...

AstraZeneca Advances AZD7760 Trial in Japan, Quietly Expanding Its Infection-Prevention Pipeline

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. AstraZeneca is running a new study called “A Multicenter, Prospectiv...

AstraZeneca Deepens NSCLC Precision Strategy With New MET Gene Profiling Study

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. AstraZeneca’s COMETA study (NCT06897748) looks at whether its drug tozorak...

AstraZeneca’s COMETA COPD Trial Nears Key Data Milestone

In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on AstraZeneca, with a price target of £160.00. According to Ti...

J.P. Morgan Reaffirms Their Buy Rating on AstraZeneca (AZN)

Let’s take a look at some recent hedge fund activity in the retail and e-commerce sector and see where the pools of money have been spent on in the...

Walmart Beats Rivals Amazon and Target in the Battle of the Hedge Funds

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. AstraZeneca’s latest update covers a Phase 1 trial titled “An Open-l...

AstraZeneca Advances AZD5004 Combo Data With Diabetes Drugs, Offering Subtle Upside for AZN Investors

In a report released today, Rajesh Kumar from HSBC downgraded AstraZeneca to a Hold, with a price target of p13,750.00. According to TipRanks, Kuma...

AstraZeneca (AZN) was downgraded to a Hold Rating at HSBC

In a report released today, Luisa Hector from Berenberg Bank maintained a Buy rating on AstraZeneca, with a price target of £160.00. Hector covers ...

Berenberg Bank Sticks to Its Buy Rating for AstraZeneca (AZN)

Guggenheim analyst Seamus Fernandez reiterated a Buy rating on AstraZeneca yesterday and set a price target of £162.00. Fernandez covers the Health...

Guggenheim Keeps Their Buy Rating on AstraZeneca (AZN)

Deutsche Bank analyst Emmanuel Papadakis maintained a Sell rating on AstraZeneca today and set a price target of £115.00. According to TipRanks, Pa...

Deutsche Bank  Keeps Their Sell Rating on AstraZeneca (AZN)

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. AstraZeneca is running a new real-world study in China to track outc...

AstraZeneca’s Real-World Lung Cancer Study in China: What Investors Should Watch

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. AstraZeneca’s latest blood cancer trial aims to improve long-term co...

AstraZeneca Advances Surovatamig Trial in High-Risk Blood Cancer

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. ROSY-S is a new Phase 3 rollover study from AstraZeneca that keeps p...

AstraZeneca Extends Anifrolumab Access With New ROSY-S Rollover Study

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. AstraZeneca is running a Phase I trial called “A Phase I, Randomized, Sing...

AstraZeneca Sharpens Andexanet Strategy With Completed Phase I Dosing Study

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. The study “An Observational Multicenter Retrospective-prospective Study of...

AstraZeneca Completes Russian Lupus Study, Building Real-World Data Edge

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. AstraZeneca has completed a large observational study in Russia titled “Mu...

AstraZeneca Completes Major Russian CKD Diagnosis Study, Setting Stage for Cardiorenal Growth

In a report released today, Justin Smith from Bernstein maintained a Buy rating on AstraZeneca, with a price target of p18,900.00. According to Tip...

Bernstein Sticks to Its Buy Rating for AstraZeneca (AZN)

AstraZeneca stock was down on Thursday after it reported a failed clinical trial, but this could present a buying opportunity for investors.


Is AstraZeneca (AZN) Stock a Buy on Today’s Dip? Here’s What Analysts Have to Say About That

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. The HELIOS study, officially titled “A Multicenter Real-world Observ...

AstraZeneca’s HELIOS Rare Disease Study Halted: What Investors Should Know

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. The non-interventional study “Non-interventional Study of Patients With Pl...

AstraZeneca Halts Russian Real-World Selumetinib Study: What It Means for AZN Investors

Citi analyst Graham Parry maintained a Buy rating on AstraZeneca yesterday. The company’s shares closed today at p14,100.00. According to TipRanks,...

AstraZeneca (AZN) Gets a Buy from Citi

Retail giants Walmart ($WMT), Target ($TGT) and Amazon ($AMZN) are offering earlier than usual back-to- school promotions this summer as American f...

Walmart Heads to Top of the Class With Parents on Early Back-to-School Deals

In a report released today, Justin Smith from Bernstein maintained a Buy rating on AstraZeneca, with a price target of £189.00. According to TipRan...

AstraZeneca (AZN) Receives a Buy from Bernstein

AstraZeneca ( ($GB:AZN) ) has issued an announcement. AstraZeneca has admitted 14,784 additional ordinary shares of $0.25 each to trading on the Lo...

AstraZeneca Adds 14,784 Shares Under Employee Schemes on LSE Main Market

AstraZeneca ( ($GB:AZN) ) has provided an announcement. AstraZeneca reported that, as of 30 June 2026, its issued share capital with voting rights ...

AstraZeneca Confirms Total Voting Rights at 1.55 Billion Shares

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. The Phase III VECTRA-01 study, officially titled “A Phase III, Multi...

AstraZeneca’s VECTRA-01 Trial Targets Next-Generation Gains in Advanced Prostate Cancer

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. AstraZeneca is running a Phase 2 study called “A Phase 2, Open-label...

AstraZeneca’s Surovatamig Trial Targets Antibody-Driven Kidney Disease

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. AstraZeneca’s new trial, “A Modular Phase I/II, Open-label, Multicenter St...

AstraZeneca Completes Early AZD9829 Trial in CD123+ Blood Cancers: What Investors Should Watch

In a report released today, Rajan Sharma from Goldman Sachs maintained a Buy rating on AstraZeneca, with a price target of £163.70. Sharma covers t...

Goldman Sachs Sticks to Their Buy Rating for AstraZeneca (AZN)

Artificial intelligence (AI) is becoming more integrated into medical labs, with major tech firms now building tools to speed up research. On Tuesd...

Anthropic Launches Claude Science AI Tool to Upend Lab and Pharma Research

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. AstraZeneca is running a new platform study in metastatic prostate c...

AstraZeneca Expands Metastatic Prostate Cancer Pipeline With New Platform Trial

Barclays analyst James Gordon CFA maintained a Buy rating on AstraZeneca today and set a price target of £165.00. Gordon CFA covers the Healthcare ...

AstraZeneca (AZN) Receives a Buy from Barclays

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. AstraZeneca is backing a new lung cancer study that uses artificial ...

AstraZeneca Advances AI-Driven Lung Cancer Risk Study in Brazil

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. AstraZeneca’s latest clinical update centers on a Phase 1 study of acalabr...

AstraZeneca Updates Phase 1 Acalabrutinib Data in Japan: What Investors Should Watch

AstraZeneca ( ($GB:AZN) ) has issued an announcement. AstraZeneca and Daiichi Sankyo have secured European Commission approval for Enhertu as the f...

AstraZeneca and Daiichi Sankyo win EU tumour‑agnostic approval for Enhertu

In a report released today, Emmanuel Papadakis from Deutsche Bank reiterated a Sell rating on AstraZeneca, with a price target of p11,500.00. Accor...

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. AstraZeneca’s new BRAVO study, officially titled “A Phase IIa, Rando...

AstraZeneca Advances BRAVO Trial for AZD2389 in Advanced Liver Fibrosis

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. AstraZeneca (AZN) has completed a Phase 1 study titled “A Single-Dose, Non...

AstraZeneca’s Opemalirsen Renal Study Completion: What Investors Should Watch Next

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. Study Overview: This Phase 0 substudy, titled “A Phase 0 Multicenter Study...

AstraZeneca’s Early Tumor Microdosing Study Completes, Setting Up the Next Move in Immuno-Oncology

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. AstraZeneca’s new mid stage trial, “A Phase IIb Study to Evaluate th...

AstraZeneca’s ARG iNAUT IPF Trial Puts New Respiratory Bet on Investors’ Radar

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. The Lung Cancer Screening Implementation Project in the Brazilian Pu...

AstraZeneca Backs Brazil Lung Cancer Screening Study With Long-Term Market Edge Potential

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. The PROSPERO study, officially titled “A Phase III, Multicentre, Randomise...

AstraZeneca’s Tozorakimab COPD Study Reaches Key Long-term Milestone

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. The BIFANG study, officially titled “A Multicentre, Single-Arm, Phas...

AstraZeneca’s BIFANG Study Targets China CRSwNP Market With Tezspire

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. The CHRONICLES COPD study, officially titled “Chronicling the COPD Patient...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AZN	$169.26	+0.59%	2.01M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AZN	$169.26	+0.6%	2.01M
3
4
5
6

AZN

AZN

Get AstraZeneca PLC Data in Excel

Get AstraZeneca PLC Data in Excel